共 164 条
[1]
de Jong FA(2007)Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein Clin Pharmacol Ther 81 42-49
[2]
Scott-Horton TJ(1999)Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors J Clin Oncol 17 685-696
[3]
Kroetz DL(1988)Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin Mol Pharmacol 34 755-760
[4]
McLeod HL(1992)Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer Drug Metab Dispos 20 706-713
[5]
Friberg LE(1992)ABC transporters: from microorganisms to man Annu Rev Cell Biol 8 67-113
[6]
Mathijssen RH(1994)Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice Cancer Res 54 3096-3100
[7]
Verweij J(1985)Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J Biol Chem 260 14873-14878
[8]
Marsh S(2004)Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors Cancer Chemother Pharmacol 54 487-496
[9]
Sparreboom A(2002)Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918 J Clin Oncol 20 2943-2950
[10]
Drengler RL(2000)Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens Clin Cancer Res 6 2685-2689